1263374-07-7Relevant academic research and scientific papers
CDK9 inhibiting compound and application thereof
-
Paragraph 0041; 0043; 0045, (2021/09/04)
The invention discloses a CDK9 inhibiting compound and application thereof, the structural formula of the CDK9 inhibiting compound is shown in the specification, A is alkyl diamine, X is halogen or H, and R is substituted benzyl. The compound can be used as a CDK9 inhibitor for down-regulating cancer cells PD-L1, and is used for tumor immunotherapy and AIDS treatment.
N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES
-
Page/Page column 61, (2012/08/08)
The present invention provides a compound of general formula:wherein Z2-Z6 include one or two nitrogen atoms as described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.
PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES
-
Page/Page column 59; 130, (2012/08/08)
The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.
N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS
-
Page/Page column 99, (2012/08/08)
The present invention provides a compound of the general formula (1): wherein one of X and Y is N and the other is an optionally substituted carbon atom, and Z2-Z5 represent one or two nitrogen atoms, as further described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals and as components of pharmaceutical compositions. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds described herein or pharmaceutical compositions comprising such compounds.
SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 1NHIBITORS AND THEIR USES
-
Page/Page column 104; 169, (2012/08/08)
The present invention provides a compound of formula (II) where R1 is a substituted alkyl, heterocyclic, or cycloalkyl, group, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tan-tomers, diastereomers, or racemates thereof, and pharmaceutical compositions comprising these compounds. Also provided are methods of using these compounds to treat a disease or condition mediated by CDK9, such as cancersand other conditions described herein
PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES
-
Page/Page column 118, (2012/08/08)
The present invention provides a pyrimidine compound of formula (I): wherein one of X and Y but not both is N, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tantomers, diastereomers, deuterated versions, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds
Heteroaryl Compounds and Their Uses
-
Page/Page column 17, (2011/02/25)
The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided is a method of treating a disease or condition mediated by CDK9.
